Sample size for equivalence trials: a case study from a vaccine lot consistency trial.
For some trials, simple but subtle assumptions can have a profound impact on the size of the trial. A case in point is a vaccine lot consistency (or equivalence) trial. Standard sample size formulas used for designing lot consistency trials rely on only one component of variation, namely, the variation in antibody titers within lots. The other component, the variation in the means of titers between lots, is assumed to be equal to zero. In reality, some amount of variation between lots, however small, will be present even under the best manufacturing practices. Using data from a published lot consistency trial, we demonstrate that when the between-lot variation is only 0.5 per cent of the total variation, the increase in the sample size is nearly 300 per cent when compared with the size assuming that the lots are identical. The increase in the sample size is so pronounced that in order to maintain power one is led to consider a less stringent criterion for demonstration of lot consistency. The appropriate sample size formula that is a function of both components of variation is provided. We also discuss the increase in the sample size due to correlated comparisons arising from three pairs of lots as a function of the between-lot variance.
Ganju
Jitendra
J
Amgen Inc., 1120 Veterans Blvd., South San Francisco, CA 94080, USA. jganju@amgen.com
Izu
Allen
A
Anemona
Alessandra
A
D002986:Clinical Trials as Topic / Q000379:methods*; D004341:Drug Evaluation / Q000379:methods*; D006801:Humans; D011786:Quality Control; D018401:Sample Size; D013810:Therapeutic Equivalency; D014612:Vaccines / Q000493:pharmacokinetics / Q000592:standards*
D014612:Vaccines